Zymeworks Inc.

David Kai Yuen Poon

Surjit Bhimarao Dixit

Thomas Spreter Von Kreudenstein

Paula Irene Lario

Eric Escobar-Cabrera

Igor Edmondo Paolo D'Angelo

Eric Escobar Cabrera

Igor Edmundo Paolo D'Angelo

The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Stable heterodimeric antibody design with mutations in the Fc domain

Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

Multivalent heteromultimer scaffold design and constructs

Growing community of inventors

Richmond, CA, United States of America

David Kai Yuen Poon